Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMN63DZ)

Drug Name

Moxetumomab pasudotox Drug Info

Synonyms

CAT-8015; GCR-8015; HA22; UNII-2NDX4B6N8F; Moxetumomab pasudotox [USAN]; Immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 heavy chain variable region fragment) fusion protein with exotoxin PE38 (Pseudomonas fragment), disulfide with immunoglobulin, anti-(human CD22 (antigen)) (synthetic Mus musculus CAT-8015 light chain fragment)

Indication

Disease Entry	ICD 11	Status	REF
Hairy cell leukaemia	2A82.2	Approved	[1]
Haematological malignancy	2B33.Y	Phase 1	[2]

Therapeutic Class

Anticancer Agents

Cross-matching ID

TTD Drug ID: DMN63DZ

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell receptor CD22 (CD22)	TTM6QSK	CD22_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hairy cell leukaemia

ICD Disease Classification

2A82.2

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-cell receptor CD22 (CD22)	DTT	CD22	1.89E-11	-0.21	-0.58

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 761104.
2	Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies
3	Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.